Top Page
Avacta Group plc
(LSE:AVCT)
Avacta Group plc (AVCT) vs. iShares MSCI United Kingdom ETF (EWC)
Avacta Group plc Business Overview & Revenue Model
Avacta Group plc Earnings Call Summary
Avacta Group plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.62M | 113.00K | 23.25M | 9.65M | 2.94M | 2.14M |
| Gross Profit | 7.55M | 113.00K | 11.24M | 4.23M | -2.50M | -973.00K |
| EBITDA | -8.46M | -17.62M | -7.50M | -34.78M | -26.69M | -16.40M |
| Net Income | -25.89M | -52.84M | -24.95M | -39.50M | -26.32M | -18.89M |
Balance Sheet | ||||||
| Total Assets | 89.29M | 48.27M | 73.19M | 92.65M | 47.00M | 67.46M |
| Cash, Cash Equivalents and Short-Term Investments | 32.53M | 12.87M | 16.63M | 41.78M | 26.19M | 47.91M |
| Total Debt | 30.60M | 22.93M | 23.51M | 62.94M | 1.70M | 2.04M |
| Total Liabilities | 41.13M | 38.99M | 51.39M | 74.21M | 5.78M | 5.53M |
| Stockholders Equity | 48.16M | 9.28M | 21.80M | 18.44M | 41.22M | 61.93M |
Cash Flow | ||||||
| Free Cash Flow | -20.57M | -23.94M | -16.13M | -17.03M | -21.82M | -12.31M |
| Operating Cash Flow | -19.14M | -23.60M | -14.87M | -16.43M | -20.51M | -10.64M |
| Investing Cash Flow | -2.44M | -1.43M | -9.00M | -25.04M | 18.70M | -21.90M |
| Financing Cash Flow | 28.36M | 26.09M | -1.30M | 56.90M | 232.00K | 51.65M |
Avacta Group plc Technical Analysis
Avacta Group plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | 130.62M | 16.63 | ― | 6.28% | 0.49% | -9.52% | |
72 Outperform | 55.37M | 5.13 | 23.84% | 2.57% | 11.92% | -33.76% | |
49 Neutral | 16.74M | -28.21 | -2.39% | ― | -5.33% | 60.20% | |
48 Neutral | £216.26M | ― | -73.02% | ― | ― | ― | |
46 Neutral | 103.78M | -7.94 | ― | ― | ― | -85.29% | |
39 Underperform | 112.27M | -8.26 | -46.75% | ― | 84.39% | -41.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Avacta Group plc Corporate Events
Avacta Group PLC announced its presentation of updated data from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology Congress. The data, focusing on patients with FAP-positive solid tumors, highlights Avacta’s ongoing efforts in the clinical development of its innovative oncology drug, which aims to improve targeted cancer therapy. This presentation underscores Avacta’s commitment to advancing its pipeline and strengthening its position in the oncology drug market.
Avacta Group PLC has announced the sale of Coris Bioconcept SRL to 3B BlackBio Dx Ltd for £2.15 million, with additional potential earn-outs. This move marks the final step in Avacta’s transition to a pure-play therapeutics company, allowing it to focus on its pre|CISION® platform for oncology treatments. The sale is expected to extend the company’s cash runway into Q1 2026 and follows a previous divestment, reinforcing Avacta’s strategic shift towards its core therapeutics business.
Avacta Group plc has announced the settlement of a quarterly principal and interest repayment for its unsecured convertible bond, reducing the principal by £2.55 million to £22.95 million. This follows a recent £3.25 million equity financing, with the Placing set to complete on 24 July 2025, reflecting the company’s ongoing financial strategies to support its operations and growth in the oncology drug market.
Avacta Group plc has successfully raised £3.25 million through a conditional placing of new ordinary shares, aimed at settling a quarterly repayment of an unsecured convertible bond. This strategic move is intended to provide the company with greater financial flexibility as it navigates a crucial commercial phase with multiple upcoming catalysts. The placing, facilitated by Zeus Capital Limited, involves a discount on the share price and represents a less dilutive option for shareholders compared to other funding routes. This financial maneuver positions Avacta to capitalize on opportunities enabled by its pre|CISION® technology, potentially enhancing its market position and stakeholder value.
Avacta Group plc announced that all resolutions, except one, were passed at its Annual General Meeting. However, more than 20% of votes were against Resolution 2, prompting the Board to engage further with shareholders to understand their concerns. This decision reflects Avacta’s commitment to maintaining open communication with its stakeholders, which could influence its future strategic decisions and shareholder relations.
Avacta Group PLC has provided a Q2 2025 business update highlighting significant progress in its strategic objectives, particularly in the clinical development of its pre|CISION® platform. The company is advancing its FAP-Dox (AVA6000) program in Phase 1b studies, showing promising efficacy in salivary gland cancers and preparing for data releases in late 2025 and 2026. Additionally, Avacta is strengthening its executive team and board, appointing new directors and a Chief Medical Officer to support its commercial partnership strategy. The company is also engaging with third parties to explore commercial opportunities and has appointed Zeus Capital as a joint broker to enhance its investor relations.
Avacta Group plc has announced the appointment of Dr. David Liebowitz as Chief Medical Officer and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz, with over 30 years of experience in oncology and drug development, will lead Avacta’s clinical strategy to advance its pipeline of targeted cancer therapies. Mr. Bogatyrenko will enhance the company’s business development strategy with his extensive experience in commercial strategy and global drug launches. These appointments are expected to strengthen Avacta’s clinical development and corporate growth strategies, potentially driving value for both patients and shareholders.
Avacta Group plc has appointed Zeus Capital as a joint broker, alongside Peel Hunt and Panmure Liberum, to strengthen its financial advisory team. This appointment involves a related party transaction due to the association of Richard Hughes, a director of Avacta, with Zeus Capital. The board, excluding Hughes, has deemed the terms fair and reasonable for shareholders, potentially enhancing Avacta’s market positioning and stakeholder confidence.
Avacta Group plc announced a promising partial response in a patient with metastatic salivary gland cancer during the dose expansion phase of its FAP-Dox (AVA6000) Phase 1b trial. This development is significant given the high unmet need for effective treatments in this rare cancer type, which lacks a preferred standard therapy. The company plans to release final data from the AVA6000 Phase 1a trial later in 2025 and will provide a business update at its upcoming Annual General Meeting.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has announced the availability of its Annual Report and Accounts for 2024 and a revised date for its Annual General Meeting (AGM), now scheduled for July 2, 2025. The AGM will be held at Peel Hunt LLP in London, with limited capacity for attendees. Shareholders are encouraged to pre-register to attend, and a business update will be provided post-AGM, accessible online for those unable to attend. This announcement reflects Avacta’s commitment to transparency and stakeholder engagement, ensuring shareholders are informed and involved in the company’s developments.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has announced its preliminary results for the year ending December 31, 2024, highlighting its transformation into a dedicated oncology biopharmaceutical company. The company has made significant progress with its pre|CISION® platform, including the completion of Phase 1a trials for its lead asset FAP-Dox (AVA6000) and plans for Phase 1b and Phase 2 trials in various cancers. Avacta has also entered a strategic collaboration with Tempus to leverage AI for smarter trials and extended its cash runway into Q1 2026 through strategic divestments. The company is focused on establishing partnerships and securing long-term financing to support its innovative pipeline and enhance shareholder value.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has announced a delay in the release of its preliminary financial results for the year ending December 31, 2024, now scheduled for June 6, 2025, due to additional audit time requested by the company’s auditors. The delay does not affect Avacta’s financial position or cash runway, and the company will conduct a live presentation for shareholders on the same day to discuss the results.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has announced the appointment of David Bryant and Richard Hughes as Non-Executive Directors, enhancing its board with their extensive experience in pharmaceuticals and capital markets. This strategic move supports Avacta’s transformation into a dedicated therapeutics company, leveraging its preCISION® platform to advance its innovative pipeline and build long-term shareholder value.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group plc has announced a delay in the publication of its preliminary results for the year ended December 31, 2024, now scheduled for June 4, 2025, due to pending audit work related to the disposal of Launch Diagnostics. Despite the delay, Avacta assures stakeholders that there is no impact on its financial position or cash runway. The company will hold a live presentation for shareholders on the same day, providing an opportunity for investors to engage with the management team.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group PLC announced it will release its audited preliminary results for the fiscal year ending December 31, 2024, on May 29, 2025. The announcement will be accompanied by a live investor presentation by CEO Christina Coughlin and CFO Brian Hahn, accessible through the Investor Meet Company platform. This event is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Avacta Group PLC announced an upcoming investor webinar featuring presentations by CEO Dr. Christina Coughlin and CSO Michelle Morrow. The webinar will discuss recent data on Avacta’s pre|CISION® candidates, FAP-Dox (AVA6000) and FAP-EXd (AVA6103), presented at the AACR Annual Meeting. This event highlights Avacta’s commitment to engaging with investors and showcasing its advancements in targeted cancer therapies, potentially strengthening its market position and stakeholder confidence.
The most recent analyst rating on (GB:AVCT) stock is a Buy with a £105.0000 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.